Damora Therapeutics Inc. – Filings and Transcripts

NASDAQ: DMRA
Share price (3/26/26): $25.63
Market cap (3/26/26): $1.546 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Automatic shelf registration

Registration of securities for employees

Ownership Filter

Winslow Garrett

Landsittel Michael

Harwin Peter Evan, Fairmount Healthcare Fund II L.P., Fairmount Funds Management LLC, Kiselak Tomas, Fairmount Healthcare Co-Invest v L.P.

Cain Christopher W.

News Filter

Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

Galecto Announces Name Change to Damora Therapeutics With Mission to Fundamentally Redefine Care for Patients With Blood Disorders

Material Definitive Agreement, Financial Statements or Exhibits

Change in Directors, Officers or Compensation, Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Other Events, Financial Statements or Exhibits

Investor Presentation

Proxies Filter

Definitive proxy

Preliminary proxy

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Other Filter

Notice of effectiveness

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC